What is Leerink Partnrs' Forecast for Immunic Q1 Earnings?

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Leerink Partnrs dropped their Q1 2025 earnings estimates for Immunic in a report released on Tuesday, April 1st. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings per share of ($0.25) for the quarter, down from their prior estimate of ($0.22). The consensus estimate for Immunic's current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunic's Q2 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.71) EPS, FY2025 earnings at ($0.71) EPS, FY2026 earnings at ($0.53) EPS and FY2026 earnings at ($0.53) EPS.

IMUX has been the topic of several other research reports. StockNews.com downgraded Immunic from a "hold" rating to a "sell" rating in a research note on Thursday, March 20th. William Blair started coverage on Immunic in a research report on Tuesday, March 25th. They issued an "outperform" rating on the stock. HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Immunic in a research report on Friday, February 21st. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $17.00 price objective on shares of Immunic in a report on Tuesday, April 1st. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Immunic has a consensus rating of "Buy" and an average target price of $13.20.

Remove Ads

Immunic Stock Up 0.3 %

Shares of IMUX traded up $0.00 during trading hours on Friday, reaching $0.90. 688,979 shares of the company traded hands, compared to its average volume of 617,688. The stock has a market capitalization of $80.96 million, a P/E ratio of -0.72 and a beta of 1.91. The business has a fifty day moving average price of $1.09 and a 200-day moving average price of $1.17. Immunic has a 12-month low of $0.84 and a 12-month high of $2.11.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Invesco Ltd. acquired a new stake in shares of Immunic during the 4th quarter valued at about $37,000. Virtu Financial LLC acquired a new stake in Immunic in the third quarter valued at approximately $50,000. HB Wealth Management LLC acquired a new stake in Immunic in the fourth quarter valued at approximately $81,000. Barclays PLC purchased a new stake in shares of Immunic in the fourth quarter valued at approximately $84,000. Finally, Jane Street Group LLC raised its stake in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after buying an additional 38,553 shares during the period. Institutional investors and hedge funds own 51.82% of the company's stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.